|
gptkbp:instanceOf
|
gptkb:drug
gptkb:dopamine_antagonist
|
|
gptkbp:approvedInUS
|
1979
|
|
gptkbp:ATCCode
|
A03FA01
|
|
gptkbp:brand
|
gptkb:Maxolon
gptkb:Reglan
|
|
gptkbp:CASNumber
|
364-62-5
|
|
gptkbp:category
|
gptkb:antiemetic
prokinetic agent
gastroprokinetic
|
|
gptkbp:contraindication
|
gptkb:pheochromocytoma
epilepsy
gastrointestinal hemorrhage
|
|
gptkbp:discoveredBy
|
gptkb:Charles_Laville
gptkb:Justin-Besançon
|
|
gptkbp:discoveredIn
|
1964
|
|
gptkbp:eliminationHalfLife
|
5–6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:genericAvailable
|
true
|
|
gptkbp:hasMolecularFormula
|
C14H22ClN3O2
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
5-HT3 receptor antagonist
5-HT4 receptor agonist
D2 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
drowsiness
extrapyramidal symptoms
tardive dyskinesia
|
|
gptkbp:usedFor
|
gptkb:gastroesophageal_reflux_disease
nausea
vomiting
gastroparesis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:A04AA01
gptkb:Parkinson_Disease,_Drug-Induced
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
metoclopramide
|